HDAC inhibitors are known to cause cell-cycle arrest by inducing CDKN1A or inhibiting CDKs and effectively suppress profibrotic fibroblast phenotypes IPF, notably offering better performance than that of pirfenidone [61]. Here, CDKN1A is linked to idiopathic pulmonary fibrosis.